Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate.

Journal of virology·2026
Same author

Novel NSAID-Se derivative YSN-1-167 against Enterovirus 71 infection by inhibiting 3D<sup>pol</sup> activity.

Antimicrobial agents and chemotherapy·2026
Same author

Electrochemically Generated ROS Water for Rapid Disinfection and Biofilm Control in Real Waters.

Microorganisms·2026
Same author

Mutation in enterovirus 71 nonstructural protein 3A increases genome replication fidelity and exhibits attenuated virulence in mice.

Journal of virology·2025
Same author

OH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via β-catenin pathway suppression.

Communications biology·2025
Same author

DENV-2 3'UTR dumbbell structure is a critical factor for viral infection and dissemination in <i>Aedes</i> mosquito.

Journal of virology·2025

Related Experiment Video

Updated: Jun 13, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K

PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application.

Zhihao Zhang1,2, Jinhu Zhou2, Peng Ni2

  • 1National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, Hubei, China.

NPJ Vaccines
|March 16, 2023
PubMed
Summary

A new SARS-CoV-2 subunit vaccine candidate, PF-D-Trimer, shows broad protection against variants. This stable, refrigerator-free vaccine platform accelerates development for future SARS-CoV-2 strains.

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K

Related Experiment Videos

Last Updated: Jun 13, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K

Area of Science:

  • Vaccinology
  • Virology
  • Immunology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, necessitates effective vaccines.
  • The SARS-CoV-2 spike protein is a key target for host immune responses.

Purpose of the Study:

  • To present preclinical studies of a broadly protective SARS-CoV-2 subunit vaccine candidate, PF-D-Trimer.
  • To evaluate antigen design, purification, vaccine efficacy, and manufacturability.

Main Methods:

  • Developed a pre-fusion trimerized Delta spike protein (PF-D-Trimer) using a Trimer Domain platform.
  • Expressed and purified PF-D-Trimer using Chinese hamster ovary (CHO) cells and immunoaffinity chromatography.
  • Formulated the vaccine with an adjuvant and assessed stability.

Main Results:

  • PF-D-Trimer induced robust immune responses in mouse, rat, and Syrian hamster models.
  • The vaccine protected K18-hACE2 transgenic mice against homologous viral challenge.
  • Induced neutralizing antibodies showed cross-reactivity against ancestral, Delta, and Omicron variants (including BA.5.2).
  • The vaccine formulation is stable for up to six months without refrigeration.

Conclusions:

  • The Trimer Domain platform enables rapid production of SARS-CoV-2 vaccines.
  • PF-D-Trimer demonstrates broad protective potential and stability, crucial for combating COVID-19.
  • This platform technology can accelerate the development of updated SARS-CoV-2 vaccines.